Literature DB >> 2651325

Clinical evaluation of a new high-flux cellulose acetate membrane.

R M Schaefer1, L Huber, U Gilge, K Bausewein, J Vienken, A Heidland.   

Abstract

One major goal of dialysis therapy has become the removal of beta 2-microglobulin (beta 2-m). The interdialytic elimination of beta 2-m was studied using a newly developed high-flux cellulose acetate (CA) membrane. The results show that high-flux CA dialyzers offer better biocompatibility than classical Cuprophan or high-flux Cuprophan devices, with regard to leukopenia, C3a desarg generation, and elastase release from polymorphonuclear (PMN) leukocytes. Compared to high-flux CA membranes, high-flux PMMA membranes induce less C3a desarg formation but comparable leukopenia. High-flux PMMA membranes, however cause greater leukocyte stimulation than CA as demonstrated by more PMN elastase release during hemodialysis. Using high-flux CA or high-flux PMMA membranes, serum beta 2-m levels decreased 32% during dialysis. Serum beta 2-m dropped 10% with high-flux Cuprophan membranes, but remained unchanged with conventional Cuprophan dialyzers. Sieving coefficients for beta 2-microglobulin (beta 2-m) were virtually zero with classical Cuprophan and 0.66 with high-flux cellulose acetate membranes. High-flux membranes made of Cuprophan and PMMA gave coefficients of 0.25 and 0.45, respectively. This indicates the high removal capacity of the new CA-membrane for substances with high molecular weight. This high-flux CA membrane thus appears to combine a good degree of biocompatibility with a high capacity for beta 2-m removal.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651325

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  2 in total

1.  A zebrafish model for uremic toxicity: role of the complement pathway.

Authors:  Nathaniel Berman; Melisa Lectura; Josh Thurman; James Reinecke; Amanda C Raff; Michal L Melamed; James Reinecke; Zhe Quan; Todd Evans; Timothy W Meyer; Thomas H Hostetter
Journal:  Blood Purif       Date:  2013-05-08       Impact factor: 2.614

2.  Section 5: Dialysis Interventions for Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.